Related Experiment Video
Updated: Jun 25, 2026

Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis
Published on: October 27, 2023
Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
C Kragelund1, C Hansen, J Reibel
1Section of Oral Medicine, Clinical Oral Physiology, Oral Pathology & Anatomy, Department of Odontology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. ckr@odont.ku.dk
This study investigated if genetic variations in cytochrome P450 enzymes (CYPs) contribute to oral lichen planus (OLP). While no link was found to poor metabolism, a specific CYP2D6 variant was more common in OLP patients, suggesting molecular mimicry may play a role.
Area of Science:
- Pharmacogenomics
- Oral Medicine
- Immunology
Background:
- Oral lichen planus (OLP) is a chronic inflammatory condition affecting oral mucosa.
- Environmental factors, including medications, are implicated in OLP development.
Purpose of the Study:
- To investigate the hypothesis that genetic polymorphisms in cytochrome P450 enzymes (CYPs) influence OLP pathogenesis.
- To determine if poor or intermediate CYP metabolism is associated with OLP.
Main Methods:
- Genotyping of 120 OLP patients and 180 controls for CYP2C9, CYP2C19, and CYP2D6 alleles with reduced function.
- Assessing drug and herbal product intake metabolized by or inhibiting CYPs.
Main Results:
- No increased prevalence of poor/intermediate CYP metabolizers in OLP patients compared to controls.
- Higher frequency of variant CYP2D6 genotypes, specifically CYP2D6*4, observed in OLP females (P < 0.05).
- CYP2D6*4 allele prevalence was significantly higher in OLP patients (50%) versus the general population (30%), suggesting a potential role.
Conclusions:
- Pharmacological pathogenesis due to poor/intermediate CYP metabolism was not substantiated for OLP.
- Molecular mimicry between CYP2D6*4 and oral pathogens like HSV1 and Candida albicans may contribute to OLP pathogenesis.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug toxicity: Idiosyncratic Reactions
Pharmacogenomics: Identification of New Drug Targets
